Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

OSAKA, Japan, March 7, 2013 /PRNewswire/ --

Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD). If approved, vedolizumab would be the first and only gut-selective biologic agent for UC and CD on the market.

"Ulcerative colitis and Crohn's disease are chronic debilitating diseases with important unmet medical needs, often affecting young people in the prime of their lives," said Asit Parikh , M.D., Ph.D., vice president, general medicine, Takeda. "We are encouraged by the findings of GEMINI, the vedolizumab Phase 3 clinical development program, which studied approximately 3,000 patients in nearly 40 countries, making it the largest IBD clinical trial program conducted to date."

Nearly four million people worldwide are affected by IBD, with UC affecting more than 500,000 people and CD affecting approximately 230,000 people in the EU.Crohn's disease and ulcerative colitis are chronic diseases that cause inflammation of the lining of the digestive tract. Inflammation caused by CD can involve varying areas of the digestive tract, while UC impacts the colon only.CD and UC can be both painful and debilitating, which may sometimes lead to serious complications and can significantly impact the quality of life for patients.

The MAA submission was supported by Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III and GEMINI LTS (Long-term Safety), which are part of the GEMINI Studies™, a four-study clinical research program to investigate the efficacy and safety of vedolizumab on clinical response and remission
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014  Dr. Navneet Sharda M.D . ... recently announced their continued investment in cutting edge cancer treatments ... at the Center and a national reputation as leaders in ... speaking with multiple cancer survivors who have undergone cancer treatment ... both his warm, friendly manner and his belief in the ...
(Date:9/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... stringent listing criteria for the NASDAQ Global Select Market ... exchange from the NYSE MKT. The company will continue ... NASDAQ Global Select Market, a segment of ... standards of any exchange in the world, requiring that ...
(Date:9/15/2014)... 2014  The Female Health Company (NASDAQ-CM: FHCO) today ... Company,s management team as Executive Vice President of Global ... that Michael Pope will retire from his ... September 15, 2014.  Following his retirement, Mr. Pope will ... Prior to joining The Female Health Company ...
Breaking Medicine Technology:Cancer Care Center Emphasizing Innovative Oncology Treatments 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... Births of multiple babies cost more and pose greater ... report. The researchers suggest that limiting embryo transfers ... some of that burden. Over the past 30 ... to older mothers and use of assisted reproductive technology, ... Wales, Australia. Their study, published online Sept. 15 ...
(Date:9/15/2014)... Array Health , an ... announced that Independence Blue Cross (Independence), ... has selected the Array Spectrum™ Private Exchange solution ... for employers with more than 100 employees. Using ... will offer employer groups a comprehensive selection of ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... in U.S. courts, Bernstein Liebhard LLP notes that a ... be useful in curbing aggression in children with ADHD ... and parent training in behavioral management techniques. According to ... children with ADHD and aggression problems, half of whom ...
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- People who,ve had ... even one of nine critical steps in their treatment is ... the United Kingdom noted patients who missed a part of ... of developing symptoms, were more likely to miss other steps ... outcomes among heart attack patients can be improved if all ...
(Date:9/15/2014)... Female college freshmen understand the benefits of eating healthy ... diets. But they lack confidence in their ability to act ... calcium, says a new University of Illinois study. , "The ... to eat a healthful diet, especially if they had to ... motivation just wasn,t strong if they were at a party ...
Breaking Medicine News(10 mins):Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4Health News:Heart Attack Patients Face Greater Death Risk if Any Treatment Step Missed: Study 2Health News:Freshman girls know how to eat healthy but lack confidence in their ability to do it 2
... for parents could go a long way toward improving ... a Wayne State University researcher believes. Deborah Ellis, ... of Medicine, has received a two-year, $418,000 grant from ... Diseases of the National Institutes of Health to develop ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
... News) -- A cardiac rehabilitation program appeared to reduce ... among patients who have suffered mild strokes or the ... found. "Overall, following the cardiac rehab intervention, the ... risk profile," study senior investigator Neville Suskin, medical director ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) -- Fred ... evolution of the public health response to human papillomavirus, or ... HPV News , a bimonthly newsletter published by the ... the 1990s. HPV is a sexually transmitted disease that ...
... Sweden: Women diagnosed with breast cancer late in life ... than younger patients, assuming they survive other age-related conditions, ... 2011 European Multidisciplinary Cancer Congress on Saturday. The results ... as well as differences in the progress of the ...
... Gardner HealthDay Reporter , THURSDAY, Sept. 22 ... the credibility of claims that a virus likely causes ... nine different labs around the United States failed to ... the basis of whether they tested positive for xenotropic ...
Cached Medicine News:Health News:Wayne State University study aims to improve diabetes management in high-risk youth 2Health News:Wayne State University study aims to improve diabetes management in high-risk youth 3Health News:Depression After Cancer Keeps Some From Follow-Up Care 2Health News:Cardiac Rehab May Cut Risk Factors After Mini-Stroke 2Health News:Stress the 'Human' in HPV, One Man Suggests 2Health News:Stress the 'Human' in HPV, One Man Suggests 3Health News:Elderly breast cancer patients risk treatment discrimination 2Health News:Elderly breast cancer patients risk treatment discrimination 3Health News:Elderly breast cancer patients risk treatment discrimination 4Health News:New Report Casts More Doubt on Virus' Link to Chronic Fatigue Syndrome 2Health News:New Report Casts More Doubt on Virus' Link to Chronic Fatigue Syndrome 3
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
These retractors are packaged singly ready for sterilization at your facility....
These retractors are packaged singly ready for sterilization at your facility....
Medicine Products: